Loading
companiesCompany
Shenzhen TargetRx
Shenzhen TargetRx is a China-based biotechnology company running 4 late-stage cancer trials of TGRX-326, TGRX-814 and TGRX-678 in non-small-cell lung cancer, hodgkin lymphoma and acute myeloid leukaemia.
Also called: Shenzhen TargetRx Co., Ltd.
Overview
Shenzhen TargetRx, based in Shenzhen, China, is a biotechnology company. TargetRx develops next-generation targeted small-molecule anticancer drugs designed to overcome drug resistance, using an AI-assisted, structure-based molecular design platform. On ClinicalTrials.gov it is the lead sponsor of 4 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing TGRX-326, TGRX-814 and TGRX-678 in non-small-cell lung cancer, hodgkin lymphoma, acute myeloid leukaemia, acute lymphoblastic leukaemia and myelodysplastic syndromes / neoplasms. The largest, NCT06082635 (TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)), plans to enrol 321 participants (actual). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
Shenzhen, CN
Scorecard
All companies#430of 1244 companies, score 8
- phase 3 +3
- modalities +2
- registry trials +3
0 approved, 1 in phase 3, 0 earlier, 0 targets, 2 registry studies. Formula on the scorecards page.
Type
Website
Phase 3small molecule
TGRX-326 is an experimental small-molecule drug from Shenzhen TargetRx in phase 3 trials for non-small-cell lung cancer, with its target not yet stated publicly.
Similar pages
- TrialA First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Shares Chronic myeloid leukaemia (CML), Myelodysplastic syndromes / neoplasms (MDS), Hodgkin lymphoma, Acute lymphoblastic leukaemia.
- JournalCurrent hematologic malignancy reports
Shares Chronic myeloid leukaemia (CML), Myelodysplastic syndromes / neoplasms (MDS), Hodgkin lymphoma, Acute lymphoblastic leukaemia.
- JournalClinical lymphoma, myeloma & leukemia
Shares Chronic myeloid leukaemia (CML), Myelodysplastic syndromes / neoplasms (MDS), Hodgkin lymphoma, Acute lymphoblastic leukaemia.
- JournalLeukemia & lymphoma
Shares Chronic myeloid leukaemia (CML), Myelodysplastic syndromes / neoplasms (MDS), Hodgkin lymphoma, Acute lymphoblastic leukaemia.
- JournalLeukemia research
Shares Chronic myeloid leukaemia (CML), Myelodysplastic syndromes / neoplasms (MDS), Acute lymphoblastic leukaemia, Acute myeloid leukaemia.
- CollectionLeukemia & Lymphoma Society (LLS)
Shares Chronic myeloid leukaemia (CML), Myelodysplastic syndromes / neoplasms (MDS), Hodgkin lymphoma, Acute lymphoblastic leukaemia.
- TrialStudy of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute lymphoblastic leukaemia, Acute myeloid leukaemia.
- TrialStudy of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute lymphoblastic leukaemia, Acute myeloid leukaemia.
cancers
drugs
Phase 3small molecule